Palisade Bio, Inc. (PALI) Stock

Palisade Bio, Inc. (PALI) is a Healthcare stock trading at $1.88 (as of 2026-06-18), with a market capitalization of $367.99M and a trailing P/E of 17.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies aimed at diseases linked to loss of the mucosal barrier in the gastrointestinal tract. Its lead program, LB1148, is an oral liquid formulation intended to inhibit digestive enzyme activity to help preserve gut integrity during intestinal stress such as reduced blood flow, infections, or surgery.

Valuation — source: SEC EDGAR (first-party)
Price	$1.88
Market Cap	$367.99M
P/E Ratio	17.7
EV / EBITDA	-8.9
Price / Book	2.89
DCF Value (model)	$-0.31
DCF Upside vs Price	-116.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-19.0%
Current Ratio	23.71
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	466.1%
FCF Growth (YoY)	9.5%

Valuation vs Sector & Industry
Stock P/E	17.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-15.4%
vs Industry	3.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	B Group, Inc. ($19.97M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	J. D. Finley
Employees	8
Country	US
IPO Date	2007-03-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.